Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 3 February 2026Expected publication date: 14 May 2026